🔎 Trials Near Me

Dachaigh › Lymphoma Cealla-T Peripheral › Pennsylvania

Sgrùdaidhean clionaigeach Lymphoma Cealla-T Peripheral ann an Pennsylvania

Tha 6 sgrùdaidhean airson Lymphoma Cealla-T Peripheral a’ lorg phàirtichean aig làraichean ann an Pennsylvania.

Bailtean ann an Pennsylvania

Teacsa sgrùdaidh oifigeil (Beurla)

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

  • University of Pittsburgh Medical Center (UPMC), Pittsburgh
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT04234048

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

  • Children's Hospital of Philadelphia, Philadelphia
A’ fastadhSgrùdadh amharc
Aoisean 0 gu 38 · Gach gnè · Air ùrachadh 1 Dàmh 2026 · NCT06131801

A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma

  • University of Pennsylvania - Abramson Cancer Center, Philadelphia
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 30 Sult 2026 · NCT07192471

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

  • University of Pittsburgh Medical Center, Pittsburgh
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06561048

AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

  • Research Site, Philadelphia
A’ fastadhÌre 1/2
Aoisean 12 agus nas sine · Gach gnè · Air ùrachadh 14 Sult 2026 · NCT06137144

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

  • Penn Medicine - Abramson Cancer Center Perelman, Philadelphia
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 24 Ògmh 2026 · NCT04068597

Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.